Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | ALPL | P05186 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29943103 | 1.00 | SCN5A (0.41) | SCN5AALDH1A1MAPK1TDP1L3MBTL1 | |
| SCHEMBL8572781 | 0.84 | ALPL (0.42) | ALDH1A1MAPK1TDP1L3MBTL1HRH4 | |
| SCHEMBL25875494 | 0.83 | RAB9A (0.39) | ALDH1A1MAPK1TDP1L3MBTL1RAB9A | |
| SCHEMBL2033955 | 0.82 | RAB9A (0.38) | ALDH1A1MAPK1TDP1L3MBTL1RAB9A | |
| SCHEMBL13019865 | 0.82 | RAB9A (0.42) | ALDH1A1MAPK1TDP1L3MBTL1RAB9A | |
| SCHEMBL4704298 | 0.81 | MAPK1 (0.43) | ALDH1A1MAPK1TDP1L3MBTL1HPGD | |
| SCHEMBL24901452 | 0.80 | ALDH1A1 (0.43) | ALDH1A1MAPK1TDP1RAB9AHPGD | |
| SCHEMBL10801181 | 0.79 | GPR3 (0.43) | SCN5AALDH1A1MAPK1TDP1L3MBTL1 | |
| SCHEMBL4573180 | 0.78 | KDM4E (0.41) | TDP1HRH4ALPLSMN1; SMN2TSHR | |
| SCHEMBL15968924 | 0.78 | KDM4E (0.41) | TDP1HRH4ALPLSMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4103557-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-02-18 | — | — | EP | disclosed |
| US-12502378-B2 | Monoacylglycerol lipase modulators for use in autism spectrum disorders | JANSSEN PHARMACEUTICA NV (BE) | 2025-12-23 | — | — | US | disclosed |
| EP-4384165-B1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-09 | — | — | EP | disclosed |
| US-20250059172-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL | NIPPON SHINYAKU CO., LTD. (JP) | 2025-02-20 | — | — | US | disclosed |
| EP-4458810-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL | Nippon Shinyaku Co., Ltd. (JP) | 2024-11-06 | — | — | EP | disclosed |
| CN-118748993-A | Indazole compounds and medicaments | 日本新药株式会社 | 2024-10-08 | — | — | CN | disclosed |
| US-20240299365-A1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-12 | — | — | US | disclosed |
| EP-4384165-A1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | Janssen Pharmaceutica NV (BE) | 2024-06-19 | — | — | EP | disclosed |
| CN-118076351-A | Monoacylglycerol lipase modulators for autism spectrum disorders | 詹森药业有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-11974987-B2 | Monoacylglycerol lipase modulators for use in autism spectrum disorders | JANSSEN PHARMACEUTICA NV (BE) | 2024-05-07 | — | — | US | disclosed |
| WO-2009062059-A2 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009062059-A2 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20070099921-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS | 2007-05-03 | — | — | US | disclosed |
| US-7049306-B2 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4. | ELAN PHARMACEUTICALS, INC. (US) | 2006-05-23 | — | — | US | disclosed |
| US-7005433-B2 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2006-02-28 | — | — | US | disclosed |
| US-20060030559-A1 | Diazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | disclosed |
| US-6911439-B2 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2005-06-28 | — | — | US | disclosed |
| US-20050074451-A1 | Methods and compositions for treating rheumatoid arthritis | ELAN PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| US-20050065192-A1 | Methods and compositions for treating rheumatoid arthritis | ELAN PHARMACEUTICALS, INC. (US) | 2005-03-24 | — | — | US | disclosed |
| US-6492372-B1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099921-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, ITGB4 | SCN5A 3192/4885ALDH1A1 260/4885MAPK1 2471/4885 |
| US-20060030559-A1 | Diazole derivatives | GRM1, GRM2, GRIN2B | SCN5A 1746/4885ALDH1A1 266/4885MAPK1 3781/4885 |
| US-11974987-B2 | Monoacylglycerol lipase modulators for use in autism spectrum disorders | LIPC, LPL, MGLL | SCN5A 1790/4885ALDH1A1 266/4885MAPK1 4715/4885 |
| US-20240299365-A1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | LIPC, LPL, MGLL | SCN5A 1790/4885ALDH1A1 266/4885MAPK1 4715/4885 |
| US-20250059172-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL | MC5R, CYP3A5, PTGIS | SCN5A 7/4885ALDH1A1 889/4885MAPK1 693/4885 |
| US-20050065192-A1 | Methods and compositions for treating rheumatoid arthritis | VCAM1, ICAM1, ITGA4 | SCN5A 1755/4885ALDH1A1 445/4885MAPK1 2645/4885 |
| US-12502378-B2 | Monoacylglycerol lipase modulators for use in autism spectrum disorders | LIPC, LPL, MGLL | SCN5A 1790/4885ALDH1A1 266/4885MAPK1 4715/4885 |
| US-20050074451-A1 | Methods and compositions for treating rheumatoid arthritis | VCAM1, ICAM1, ITGA4 | SCN5A 1755/4885ALDH1A1 445/4885MAPK1 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.